INBAL AIDA, M.D. **05.07.12**

CURRICULUM VITAE

Name: Inbal Aida **I.D. No.:** 12290466

Faculty: Medicine **Department:** Hematology

EDUCATION

1970 – 1976 Medical student at Sackler Faculty of Medicine, Tel-Aviv University, Israel

ACADEMIC EXPERIENCE

1985 – 1988 Research Fellowship, Harvard Medical School, Hematology Division, Brigham & Womens Hosp. Boston, MA, USA, (Prof. Handin RI)

1991 – 1992 Visiting Professor, Washington University, Howard Hughes Medical Institute Research Laboratories at Prof. J. E. Sadler's Laboratory, St. Louis, MO, USA

2002 - 2006 Head Division of Hematology, Sackler Faculty of Medicine, Tel Aviv University

2007-present Professor in Hematology, Tel-Aviv University, Sackler Faculty of Medicine, Israel

2009 - present Head of Cathedra (Hosse Henrike de Faiba) of Thrombosis and Hemostasis Research, Tel Aviv University

CLINICAL EXPERIENCE

1977 – 1979 Fellowship in Hematology, Sheba Medical Center, Tel-Hashomer

1979 – 1982 Resident in Internal Medicine Meyer Hospital, Kfar Saba

1983 Israeli Board Certified Hematologist

2002 –2005 Acting Director Institute of Thrombosis and Hemostasis, Department of Hematology, Sheba Medical Center, Tel Hashomer

2006 - present Director, Thrombosis & Hemostasis Unit, and Hematology Clinic Hematology Department, Beilinson Hospital, Rabin Medical Center, Petach Tikva.

E. ACADEMIC AND PROFESSIONAL AWARDS

1984 Ben-Gurion Research Grant

1988-1991	Israel-USA Binational Science Foundation Grant
1991-1993	Ministry of Health-Chief Scientist Grant
1992	European Molecular Biology Organization (EMBO) Grant
1996-1998	Ministry of Health, Chief Scientist Grant
1998	Tel-Aviv University Shlesac Grant
1999	NitroMed Research Grant
1997	Patent: A S-Nitrosated peptide fragment of von Willebrand protein as a Unique Antiplatelet Agent PCT Application Serial No. 09/381,261
2004	Patent: Use of an injectable Factor XIII preparation for angiogenesis. No: 2004/M001 – A84
2003-2005	Aventis-Behring Research Grant
2004-2006	Bio Products Laboratories (BPL) Research Grant
2008	Sanofi-Aventis Research Grant
2011	Patent: FGL-2 protjrombinase as a diagnostic tool for malignancy. No. 61/364,031;
2011-	"Nofar" Research Grant, Chief Scientist, Ministry if Health
	Research Grant
2011	"Musia" Research Grant of Clalit

F. MEMBERSHIP IN PROFESSIONAL SOCIETIES

1977	Israel Medical Association
1980	Israel Society of Hematology and Blood Transfusion
1989	International Society on Thrombosis and Haemostasis
1990	American Society of Hematology
1992	Member of Steering Committee of World Consortiuum on von Willebrand Factor Mutations and Polymorphisms
1995	Member of ETRO Workshop Party on Factor XIII

1997	Member of the Scientific Standardization Committee on VWF of the International Society on Thrombosis and Haemostasis.
2005 – 2008	Chairman, Israeli Society of Thrombosis and Hemostasis
2007 – present	Co-Chairman for Factor XIII and Fibrinogen Scientific Subcommittee of International Society of Thrombosis and Haemostasis (ISTH)

G1. SUPERVISION OF M.Sc. AND Ph.D. STUDENTS

1992-1995	Ph.D. student. Talma Englander, Section of Cell Biology, Sackler Faculty of Medicine, Tel-Aviv University
Thesis:	"Detection of mutations within the gene of von Willebrand disease, and their expression in COS-7 cells"
1993	M.Sc. Student, Shula Harari, Section of Cell Biology, Sackler Faculty of Medicine, Tel-Aviv University
Thesis:	"Identification of mutations in the von Willebrand Factor gene responsible for type I von Willebrand disease-clarification of the genotype of type I von Willebrand disease"
2001-2006	Ph.D Sudent Alex Visokovsky, Section of Cell Biology, Sackler Faculty of Medicine, Tel-Aviv University
Thesis:	"Identification and expression of mutations causing Hereditary Factor FXIII Deficiency ."
2002-2006	M.Sc. Student, Beatris Tekochiano, Section of Cell Biology, Sackler Faculty of Medicine, Tel-Aviv University
Thesis:	"Molecular Basis of Familial Thrombocytosis"
2004-2006	M.Sc. Student, Tanya Karp, Life Sciences, Bar Ilan University
Thesis:	Effect of coagulation factor XIII on processes of angiogenesis
2004 – present	Ph.D Student Sagi Raz, Department of Biomedical Engineering, Faculty of Engineering, Tel-Aviv University
Thesis:	The effect(s) of flow characteristics on thrombus formation rate and thrombus size
2007 – present	Ph.D. Nataly Tarasenko. Student Section of Cell Biology, Sackler Faculty of Medicine, Tel-Aviv University
Thesis	Histone Deacetilase inhibitory anticancer effects: Mechanism of action and selectivity

G2. SUPERVISION OF BASIC SCIENCE PROJECTS OF M.Ds

1992 Spitzer Thomas, M.D.

Title of Project: Detection of changes in RAS oncogen in tumors of thyroid.

Name of Hospital: Belinson Medical Center

1996 Monica Feldman, M.D. Sheba Medical Center

Title of Project: Evaluation of anti-thrombotic properties of recombinant von Willebrand factor fragment AR545C.

Name of Hospital: Sheba Medical Center

2007 Eli Karniel, M.D., Meir Hospital, Kfar Saba

Title pf project: Assessment of Coagulation Factor XIII as a Protein Disulphide Isomerase (PDI)

Name of Hospital: Belinson Medical Center

2010 Ariella Tvito, M.D., Asaf Harofe Medical Center

Title of project: Effect of Coagulation Factor XIII as Protein Disulphide Isomerase (PDI) on platelet function in patients with factor XIII deficiency

Name of Hospital: Belinson Medical Center

2011 Avi Lider M.D., Meir Hospital, Kfar Saba

Title of project: The role of disulfide exchange and free thiols in the post ligation phase of IIbIIIa-medited cell adhesion

Name of Hospital: Belinson Medical Center

LIST OF PUBLICATIONS

1. **Inbal A**, van Dyk D, Jutrin I, Ravid M. Primary thrombocytopenia. **Harefuah** 100:278, 1981.

2. Van Dyk D, **Inbal A**, Kraus L, et al. The watery diarrhea syndrome with hypercalcemia – a symptomatic response to phosphate buffer. **Hepato Gastroenterol** 28:58-59, 1981.

3. Lang R, **Inbal A**, Jutrin I, Ravid M. Recurrent venous thrombosis – the sole manifestation of an occult myeloproliferative disease. **Isr J Med Sci** 18:705, 1982.

4. **Inbal A**, Akstein E, Barak I, Meytes D, Many A. Cyclic Leukocytosis and long survival in chronic myeloid leukemia. **Acta Haematol** 69:353, 1983.

5. **Inbal A**, Joshua H, Shaklai M. Autoerythrocyte sensitization – a case report and review of the literature. **Harefuah** 107:385-387, 1984.

6. Tamir R, Levin R, **Inbal A**, Heller I, Theodor E. High output cardiac failure in plasma cell leukemia. **Isr J Med Sci** 21:897, 1985.

7. **Inbal A**, Avidor I, Nemesh L, Shaklai M. Persistent lymphocytosis in sarcoidosis. An unusual feature in sarcoidosis. **Acta Haematol** 74:164, 1985.

8. Prokocimer A, **Inbal A**, Gelber M, Shohat B, Ben-Bassat M, Shaklai M. Hemophagocytosis simulating malignant histiocytosis, a terminal event of myelodysplastic syndrom. **Acta Haematol** 74:164-167, 1985.

9. Manor RS, Axer-Siegel R, Cohen S, **Inbal A**, Ben-Sira I. Bilateral anterior ischemic optic neuropathy, pseudoxantoma elasticum and platelet hyperaggregability. **Neuroophthalmol** 6:173, 1986.

10. Gutman H, Deutsch AA, **Inbal A**, Joshua H, Reiss R. Malignant lymphoma metastatic to the breast. **Breast Dis** 1:143, 1988.

11. Mor F, Beigel M, **Inbal A**, Gorwen S, Wysenbeek A. Hepatic infarction in a patient with the lupus anticoagulant. **Art Rheum** 34:491, 1989.

12. Blickstein D, Shaklai M, **Inbal A**. Warfarin antagonism by avocado. **Lancet** 337:914-915, 1991.

13. Shmueli H, Pitlik SD, **Inbal A,** Rosenfeld JB. Pelger-Huet anomaly mimicking shift to the left. **Netherlands J Med** 432:168-170, 1993.

14. Shapiro M, Cohen J, **Inbal A**, Singer P. Clinical cross-reactivity between danaparoid and heparin antibodies successfully managed with bivalirudin. **Isr Med Assoc J,** 2009, 11:188-90.

15. **Inbal A**. Acquired von Willebrand disease, plasma cell dyscrasia, and angiodysplasia: more than a coincidence? **Isr J Med Sci** 26:518-519, 1990.

16. Blickstein D, **Inbal A**. Gene therapy: Science fiction or reality. **Harefuah** 124:784-787, 1993.

17. Bairey O, **Inbal A.** Treatment of bleeding disorders by desmopressin. **Harefuah** 125:105-107, 1993.

18. **Inbal A**. von Willebrand factor and von Willebrand disease. **Harefuah** 120:478-482, 1991.

19. **Inbal A**. Acquired abnormalities of coagulation: Factors to consider in patients with unexpected bleeding. **Isr Med Sci** 31:448-449, 1995.

20. **Inbal A.** S-nitrosoderivative of a recombinant fragment of von Willebrand factor (S-nitroso-AR545C) : A unique antithrombotic agent. **Isr Med Assoc J** 1:290-291, 1999.

21. **Inbal A**, Modan M, Many A. A retrospective study of patients with chronic myeloid leukemia diagnosed and treated at the Chaim Sheba Center during the years 1966-1976. **Isr J Med Sci** 14(12):1259,1978.

22. Avissar N, **Inbal A**, Rabisadeh E, Shaklai N. Interaction of spectrin with hemin disaggregate spectrin associations. **Biochem Intern** 8:113-120, 1984.

23. **Inbal A**, Januszewicz E, Rabinowitz M, Shaklai M. A therapeutic trial with low dose cytarabine in myelodysplastic syndromes and acute leukemia. **Acta Haematol** 73:71, 1985.

24. Loscalzo J, **Inbal A**, Handin RI. Von Willebrand protein facilitates platelet incorporation in polymerizing fibrin. **J Clin Invest** 78:1112, 1986.

25. **Inbal A**, Modan M, Weitz Z, Lahav M, Shoenfeld N, Atsmon A, Shaklai M. Lymphocyte urosynthase in non-Hodgkin lymphoma. An indicator of disease extensiveness. **Cancer** 59:89, 1987.

26. **Inbal A**, Loscalzo J. Clycocalcin binding to von Willebrand factor absorbed onto collagen-coated or polystyrene surface. **Thromb Res** 56:347, 1989.

27. Ewenstein BM, **Inbal A**, Pober J, Jandin RI. Molecular studies of von Willebrand's disease: Reduced von Willebrand factor biosynthesis, storage and release in endothelial cells derived from patients with type I von Willebrand's disease. **Blood** 75:1466-1472, 1990.

28. **Inbal A**, Handin R. Two Stu I polymorphisms in the 5' region of the von Willebrands factor (vWF) gene. **Nucl Acid Res** 18:4959, 1990.

29. Bairey O, Shaklai M. **Inbal A**. Haemarthrosis in patients with mild coagulation factor deficiency. **Blood Coag Fibrinol** 2:669-671, 1991.

30. **Inbal A**, Kornbrot N, Zivelin A, Shaklai M, Seligsohn U. The Inheritance of type I and type III von Willebrand's disease in Israel: Linkage analysis, carrier detection and prenatal diagnosis using three intragenic restriction fragment length polymorphisms. **Blood Coag Fibrinol** 3:73-83, 1992.

31. **Inbal A**, Seligsohn U, Kornbort N, Brenner B, Harrison P, Randi A, Rabinowitz I, Sadler JE. Characterization of three mutations causing von Willebrand disease type IIA in five unrelated families. **Thromb Haemost** 67:618-622, 1992.

32. Wilbourn B, Harrison P, Lawrie A, Leroy F, Rowley M, Bevan D, **Inbal A**, Savidge G. Unique expression of von Willebrand factor by type IIA von Willebrand's disease endothellial cells. **Br J Haematol** 81:401-406, 1992.

33. Hodak E, Trattner A, David M, Kornbort N, Modan B, Lurie H, Laurie A, Harrison P, Sandbank M, **Inbal A**. Quantitative and qualitative assenssment of plasma von Willebrand factor in classical Kaposi sarcoma. **J Amer Acad Dermatol** 28:217-221, 1993.

34. **Inbal A**, Handin E. Two Taq I Polymorphisms in the 5' region of the von Willebrand factor gene. **Nucl Acid Res** 17:10143, 1989.

35. **Inbal A**, Englander T, Kornbort N, Randi AM, Castman G, Mannucci PM, Sadler JE. Identification of three candidate mutations causing IIA von Willebrand disease using a rapid non-radioactive allele specific hybridization method. **Blood** 82:830-836, 1993.

36. **Inbal A**, Blickstein D, Kornbort N, Brenner B, Martinowitz U, Epstein D. Evaluation of solvent/detergent treated plasma in the management of patients with hereditary and acquired coagulation disorders. **Blood Coagul Fibrinol** 4:599-604, 1993.

37. **Inbal A**, Kornbrot N, Harrison P. Randi AM, Sadler JE. Effect of type IIB von Willebrand disease mutation Arg (545) Cys on platelet glycoprotein Ib binding. Studies with recombinant von Willebrand factor. **Thromb Haemost** 70:1058-1062, 1993.

38. **Inbal A**, Shaklai M, Avissar N, Kuritzky A, Schejter A, Ben-David E, Shanske S, Garty B. Myopathy, lactic acidosis and sideroblastic anemia: A new syndrome. **Amer J Clin Genet** 55:272-278, 1995.

39. **Inbal A**, Kornbrot N, Mannucci PM, Sadler JE. Very low frequency of "Normandy type: mutations among type 1 von Willebrand disease families. **Thromb Haemost** 73:324, 1995.

40. Englander T, Lattuada A, Mannucci PM, Sadler JE, **Inbal A**. Analysis Arg834Gln and Val902Glu Type 2A von Willebrand disease mutations. Studies with recombinant von Willebrand factor and correlation with patient characteristics. **Blood** 87:2788-2794, 1996.

41. **Inbal A**, Bank I, Zivelin A, Varon D, Dardik R, Shapiro R, Rosenthal E, Shenkman B, Gitel S, Seligsohn U. Acquired von Willebrand disease in a patient with angiodysplasia resulting from immune-mediated clearance of von Willebrand factor. **Br J Haematol** 96:179-182, 1997.

42. **Inbal A**, Kenet G, Zivelin A, Yermiyahu T, Tamari H, Gitel S, Eshel G, Duchemin J, Aiach M, Seligsohn U. Purpura fulminans induced by disseminated intravascular coagulation following infection in 2 unrelated children with double heterozygosity for factor V Leiden and protein S deficiency. **Thromb Haemost** 77:1086-1089, 1997.

43. **Inbal A**, Yee VC, Kornbrot N, Zivelin A, Brenner B, Seligsohn U. Factor XIII deficiency due to a Leu660Pro mutation in the factor XIII subunit-A gene in three unrelated Palestinian Arab families. **Thromb Haemost** 77:1062-1067, 1997.

44. Gurevitz O, Goldfarb A, Hod H, Feldman M, Shenkman B, Varon D, Eldar M, **Inbal A**. Recombinant von Willebrand factor fragment Arg545Cys inhibits platelet aggregation and enhances thrombolysis with rtPA in a rabbit thrombosis model. **Arterioscler Thromb Vasc Biol** 18:200-207, 1998.

45. Salomon O, Steinberg DM, Zivelin A, Gitel S, Dardik R, Rosenberg N, Berliner S, **Inbal A**, Many A, Lubetsky A, Varon D, Martinowitz U, Seligsohn U. Single and combined prothrombotic factors in pateints with idiopathic venous thromboembolism: prevalence and risk assessment. **Arterioscler Thromb Vasc Biol** 19:511-518, 1999.

46. Lubetsky A, Schulman S, Varon D, Martinowitz U, Kenet G, Gitel S, **Inbal A**. Safety and efficacy of continuous infusion of a combined factor VIII-von Willebrand factor (vWF) concentrate (Haemate P™) in patients with von Willebrand disease. **Thromb Haemost** 81:229-233, 1999.

47. **Inbal A**, Freimark D, Modan B, Chetrit A, Hod H, Rosenberg N, Dardik R, Baron Z, Seligsohn U. Synergistic effects of prothrombotic polymorphisms and atherogenic factors on the risk of myocardial infarction in young males. **Blood** 93:2186-2197, 1999.

48. Kenet G, Freedman JE, Michelson AD, Brand N, Loscalzo J, **Inbal A**. Plasma glutathione peroxidase deficiency and platelet insensitivity to nitric oxide in children with familial stroke. **Arterioscler Thromb Vasc Biol** 19:2017-2023, 1999.

49. Zivelin A, Gitel S, Griffin JH, Xu X, Fernandez JA, Martinowitz U, Cohen Y, Halkin H, Seligsohn U, **Inbal A**. Extensive venous and arterial thrombosis induced by a specific inhibitor to activated protein C: A new mechanism for activated protein C resistance. **Blood** 94:895-901, 1999.

50. **Inbal A**, Gurevitz O, Eskaraev R, Feldman M, Varon D, Tamarin I, Eldar M, Loscalzo J. Unique antiplatelet effects of a novel S-nitrosoderivative of a recombinant fragment

of von Willebrand factor, AR545C: In vitro and ex vivo inhibition of platelet function. **Blood** 94:1693-1700, 1999.

51. Dardik R, Varon D, Savion N, Eskaraev R, Tamarin I, **Inbal A.** Recombinant fragment of von Willebrand factor AR545C prevents platelet adhesion to thrombin-treated endothelial cells under flow by inhibiting thrombin-induced platelet activation. **Br J Haematol** 109:512-518, 2000.

52. Kenet G, Sadetzki S, Murad H, Martinowitz U, Rosenberg N, Gitel S, Rechavi G, **Inbal A**. Factor V Leiden and antophospholipid antibodies are significant risk factors for ischemic stroke in children. **Stroke** 31:1283-1288, 2000.

53. Gurevitz O, Skutelsky E, Eldar M, Tamarin I, Shenkman B, Eskaraev R, Varon D, Castel D, Loscalzo J, **Inbal A**. S-nitrosoderivative of a recombinant fragment of von Willebrand factor (S-nitroso-AR545C) inhibits thrombus formation in guinea pig carotid artery thrombosis model. **Thromb** Haemost 84:912-917, 2000.

54. Loscalzo J, Freedman J, **Inbal A**, Keaney JF Jr, Michelson AD, Vita JA. Nitric oxide insufficiency and arterial thrombosis. **Trans Am Clin Climatol Assoc** 111:158-53, 2000**.**

55. Salomon O, Rosenberg N, Zivelin A, Steinberg DM, Kornbrot N, Dardik R, **Inbal A**, Seligsohn U. Methionine syntase A2756G and methylenetetrahydrofolate reductase A1298C polymorphisms are not risk factors of idiopathic venous thromboembolism. **Hematol J** 2:38-41, 2001.

56. Luboshitz J, Lubetsky A, Schliamser L, Kotler A, Tamarin I, **Inbal A**. Pharmacokinetic studies with FVIII/von Willebrand factor concentrate can be a diagnostic tool to distinguish between subgroups of patients with acquired von Willebrand syndrome. **Thromb Haemost** 85:806-9, 2001.

57. Hardy B, Indjtia L, Rodionov G, Raiter A, **Inbal A**. Treatment with BAT monoclonal antibody decreases tumor burden in a murine model of leukemia/lymphoma. **Int J Oncol** 19:897-902, 2001.

58. Streifler JY, Rosenberg N, Chetrit A, Eskaraev R, Sela BA, Dardik R, Zivelin A, Ravid B, Davidson J, Selighson U, **Inbal A.** Cerebrovascular events in patients with significant stenosis of the carotid artery are associated with hyperhomocysteinemia and platelet antigen 1 (Leu33Pro) polymorphisms. **Stroke** 32:2753-2758, 2001.

59. Rosenberg N, Zivelin A, Chetrit A, Dardik R, Kornbrot N, **Inbal A**. Effects of platelet membrane glycoprotein polymorphismson the risk of myocardial infarction in young males. **Isr Med Assoc J** 4:411-414, 2002.

60. **Inbal A**. Management of Thrombosis during Pregnancy. Editorial. **Isr Med Assoc J** 4:813-14, 2002.

61. Dulitzky M, Cohen SB, **Inbal A**, Seidman DS, Soriano D, Lidor A, Mashiach S, Rabinovici J. Increased prevalence of thrombophilia among women with severe ovarian hyperstimulation syndrome. **Fertil Steril** 77:463-467, 2002.

62. Lubetsky A, Martinowitz U, Luboshitz J, Kenet G, Keller N, Tamarin I, **Aida Inbal**. Efficacy and Safety of a Factor VIII - Von Willebrand Factor Concentrate 8Y: Stability, Bacteriological Safety, Pharmacokinetic Analysis and Clinical Experience. **Hemophilia** 8:622-628, 2002.

63. Carp H, Dolitzky M, Tur-Kaspa I, **Inbal A**. Hereditary thrombophilias are not associated with a decreased live birth rate in women with recurrent miscarriage. **Fertil Steril** 78:58-62**,** 2002.

64. Dardik R, Shenkman B, Tamarin I, Eskaraev R, Harsfalvi J, **Inbal A**. Factor XIII mediates adhesion of platelets to endothelial cells through $\alpha_v\beta_3$ and glycoprotein IIb/IIIa integrins. **Thrombosis Research** 105:317-323, 2002.

65**.** Carp H, Salomon O, Seidman D, Dardik R, Rosenberg N, **Inbal A.** Prevalence of genetic markers for thrombophilia in recurrent pregnancy loss. **Hum Reprod** 17:1633-1637, 2002.

66. Carp H, Dolitzky M, **Inbal A**. Thromboprophylaxis Improves The Live Birth Rate In Women With Consecutive Recurrent Miscarriages And Hereditary Thrombophilia. **J Thromb Haemost** 1:433-438, 2003.

67. Shenkman B, **Inbal A**, Tamarin I, Lubetsky A, Savion N, Varon D. Diagnosis of thrombotic thrombocytopenic purpura based on modulation by patient plasma of normal platelet adhesion under flow condition. **Br J Haematol** 120:597-604, 2003.

68. Dardik R, Solomon A, Loscalzo J, Eskaraev R, Bialik A **Inbal A**. Novel proangiogenic effect of Factor XIII (FXIII) mediated by suppression of thrombospondin1 expression (TSP-1). **Arterioscler Thromb Vasc Biol** 23:1472-1477, 2003.

69 **Inbal A**, Muszbek L. Coagulation factor deficiencies and pregnancy loss. **Semin Thromb Haemost** 29:171-174, 2003.

70. Carp H, Dardik R, Lubetsky A, Eskaraev R, Rosenthal E, **Inbal A**. Prevalence of circulating procoagulant microparticles in women with recurrent miscarriage: A case controlled study. **Hum Reprod** 19:191-5, 2004.

71. Casas K, Bykhovskaya Y, Mengesha E, Huiying Yang DW, Taylor K, **Inbal A**, Fischel-Ghodsian N. Gene responsible for mitochondrial myopathy and sideroblastic anemia (MSA) maps to chromosome 12q24.33. **Am J Med Genet** 127:44-49. 2004.

72. **Inbal A**, Muszbek L, Lubetsky A, Katona E, Levi I, Karpati L, Nagler A. Platelets but not contribute to the plasma levels of factor XIII of subunit A in patients undergoing autologous peripheral blood stem cell transplantation. **Blood Coagul Fibrinol** 15:249-253, 2004.

73. Bykhovskaya Y, Casas K, Mengesha E, **Inbal A**, Fischel-Ghodsian N. Missense mutation in pseudouridine synthase (PUS1) causes mitochondrial myopathy and sideroblastic anemia (MLASA). **Am J Hum Genet** 74:1303-1308. 2004.

74. **Inbal A**, Lubetsky A, Shimoni A, Dardik R, Sela BA, Eskaraev R, Levi I, Shem-Tov N, Nagler A. Assessment of the Coagulation Profile in Hemato-Oncological Patients Receiving ATG Based Conditioning Treatment for Allogeneic Stem Cell Transplantation – a Randomized Controlled Study. **Bone Marrow Transplant** 34:459-463, 2004.

75. Vysokovsky A, Saxena R, Landau M, Zivelin A, Eskaraev R, Rosenberg N, Seligsohn U, **Inbal A**. Seven novel mutations in the Factor XIII A-subunit gene causing hereditary Factor XIII deficiency in ten unrelated families. J Thromb Haemost 2:1790-7, 2004.

76. Dardik R, Loscalzo J, Eskaraev R, Inbal A. Molecular mechanisms underlying the proangiogenic effect of factor XIII (FXIII). Arteriosc Thromb Vasc Biol 25:526-532, 2005.

77. Amir Inbal, Aharon Lubetsky, Tanya Karp, David Castel, Aviv Shaish, Gerhardt Dickneitte, Laszlo Modis, Laszlo Muszbek and **Aida Inbal**. Impaired wound healing in factor XIII deficient mice. Thromb Haemost 94:432-437, 2005.

78. Rima Dardik, Jonathan Leor, David Castel, Ginette Schiby, Aviv Shaish, Gerhardt Dickneitte, Joseph Loscalzo, and **Aida Inbal**. Evaluation of pro-angiogenic activity of factor XIII (FXIII) in murine models of heterotopic heart allografts and FXIII-deficient mice. **Thromb Haemost** 2006, 95: 546-50.

79. Alex Vysokovsky, Nurit Rosenberg, Rima Dardik, Uri Seligsohn, **Aida Inbal**. Effect of four missense mutations in the factor XIII A-subunit gene on protein stability: studies with recombinant proteins. **Blood Coagul Fibrinolysis**. 2006, 17: 125-30.

80. Alex Vysokovsky, Nurit Rosenberg, Rima Dardik, Uri Seligsohn, **Aida Inbal**. Effect of four missense mutations in the factor XIII A-subunit gene on protein stability: studies with recombinant proteins. **Blood Coagul Fibrinolysis**. 2006, 17: 125-30.

81. Dolitzky Mordechai, **Inbal Aida**, Weiss A, Segal Y, Brenner Benjamin, Carp Howard. A randomized study of thromboprophylaxis in women with unexplained consecutive recurrent miscarriages. **Fertil Steril,** 2006, 86:362-6.

82. Rima Dardik, **Aida Inbal**. Complex formation between tissue transglutaminase II (tTG) and Vascular Endothelial Growth Factor Receptor 2 (VEGFR-2): Proposed mechanism for modulation of endothelial cell response to VEGF. **Experimental Cell Research** 312:2973-82, 2006

83. Tecuceanu Noa, Rima Dardik, Ester Rabizada, Pia Raanani, **Aida Inbal.** A family with Hereditary Thrombocythemia and normal genes for thrombopoietin and c-Mpl. **Br J Haematol** 135:348-51,2006

84. Uri Seligsohn, Ariella Zivelin and **Aida Inbal**. Inherited deficiencies of coagulation factors II, V, VII, X, XI, and XIII and combined deficiencies of factors V and VIII and of the vitamin K-dependent factors. **In: Williams Hematolody**, 7th Edition, 2006, pp. 1887-1908.

85. **Aida Inbal** and Howard Carp. Defects in coagulation factors leading to recurrent pregnancy loss. **In: Recurrent Pregnancy Loss. Causes, Controversies and Treatment. Publishers Informa Healthcare.** Ed. HJA Carp, 2006, pp. 127-138

86. Dardik R, Loscalzo J, **Inbal A**. Factor XIII and angiogenesis. **J Thromb Hemost** 4:19-25, 2006.

87. **Inbal A,** Dardik R. Role of coagulation factor XIII (FXIII) in angiogenesis and tissue repair. **Pathophysiol Haemost Thromb.** 2006;35 :162-165 (I.F 1.129; rank: 55 of 63)

88. Rima Dardik, Tanya Krapp, Ester Rosenthal, Joseph Loscalzo**, Aida Inbal.** Effect of FXIII on monocyte and fibroblast function. **Cellular Physiology and Biochemistry** 19: 113-120, 2007

89. MB Hashemi Soteh, John Anson, **Aida Inbal**, Ian R Peake, Ann C Goodeve. Re-evaluation of three Israeli families initially diagnosed with type 1 von Willebrand disease in light of the ISTH update on von Willebrand factor pathophysiology and classification. **Haemophilia** 1-4, 2008

90. Peyvandi F, Cattaneo M, **Inbal A,** De Moerloose P, Spreafico M. Rare bleeding disorders. **Haemophilia 14 (Suppl. 3) 202-210, 2008.**

91. Tarasenko N, Nudelman A, Tarasenko I, Entin-Meer M, Hass-Kogan D, **Inbal A**, Rephaeli A. Histone deacetylase inhibitors: the anticancer, antimetastatic and antiangiogenic activities of AN-7 are superior to those of the clinically tested AN-9 (Pivanex). Histone deacetylase inhibitors: the anticancer, antimetastatic and antiangiogenic activities of AN-7 are superior to those of the clinically tested AN-9 (Pivanex). **Clin Exp Metastasis** 2008;25:703-16

92. Lahav J, Karniel E, Bagoly Z, SheptovitskyV, Dardik R, **Inbal A**. Coagulation factor XIII serves as protein disulfide isomerase. Thromb Haemost 2009; 101, 840-844

93. Torocsik D, Szeles L, Paragh G, Rakosy S, Balazs M, Nagy L, **Inbal A**, Adany R. Factor XIII-A is involved in the regulation of gene expression in alternatively activated human macrophages. **Throm Haemost** 2010; 104: 709-717.

94. **Inbal A.**Von Willebrand disease: diagnostic and treatment dilemmas. **Harefuah**, 2010 149(5):283-7, 336

95. Shapiro M, Cohen J, **Inbal A**, Singer P. Clinical cross-reactivity between danaparoid and heparin antibodies successfully managed with bivalirudin. **Isr Med Assoc J**, 2009, 11(3):188-90.

96 Equinox Investigators. Efficacy and safety of once weekly subcutaneous idrabiotaparinux in the treatment of patients with symptomatic deep venous thrombosis. **J Thromb Haemost** 2011; 9:92-9

97 Tarasenko N, Kessler-Icekson G, Boer P, **Inbal A**, Schlesinger H, Phillips DR, Cutts SM, Nudelman A, Rephaeli A.The histone deacetylase inhibitor butyroyloxymethyl diethylphosphate (AN-7) protects normal cells against toxicity of anticancer agents while augmenting their anticancer activity. **Invest New Drugs** 2012; 30:130-43

98 Gideon Y. Stein, Dorit Blickstein, Jerome Orlin, Galit Sarig and **Aida Inbal**. Long-Term Response to Rituximab in Patients with Relapsing Thrombotic Thrombocytopenic Purpura. **IMAJ** 2011; 13: 398-401

99 Tarasenko N, Cutts SM, Phillips DR, **Inbal A**, Nudelman A, Kessler-Icekson G, Rephaeli A.Disparate Impact of Butyroyloxymethyl Diethylphosphate (AN-7), a Histone Deacetylase Inhibitor, and Doxorubicin in Mice Bearing a Mammary Tumor. **PLoS One** 2012;7(2):e31393. Epub 2012 Feb 23.

100 **Inbal A,** Oldenburg J, Carcao M, Rosholm A, Tehranchi R, Nugent D. Recombinant factor XIII: A safe and novel treatment for congenital factor XIII deficiency. **Blood** 2012, 119: 5111-7